Discover trends, market shifts, and competitive outlooks for the psoriasis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Psoriasis Market Size From 2025 to 2034?

The size of the psoriasis market has expanded swiftly in the past years. The market is projected to escalate from a value of $26.56 billion in 2024 to around $29.5 billion in 2025, with a compound annual growth rate (CAGR) of 11.1%. This growth over the historic period is largely due to factors such as epidemiology, enhanced patient awareness and education, along with improved healthcare infrastructure and accessibility.

The market size for psoriasis is anticipated to experience substantial growth in the coming years. It is predicted that by 2029, the market will increase to $42.34 billion, reflecting a compound annual growth rate (CAGR) of 9.4%. This growth during the projected period is linked to regulatory approvals, patient choices, an aging population, enhanced consciousness, and the emergence of new therapies. The forecast period will also see significant trends like advancements in R&D, the use of biologics and targeted therapies, oral small molecule therapies, personalized medical treatment, digital health and telemedicine, patient-focused care, biosimilars, and the disruption by artificial intelligence and machine learning.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp

Which Primay Drivers Are Accelerating Growth in the Psoriasis Market?

The Psoriasis market is being propelled by an increase in the number of patients suffering from psoriasis. The condition of psoriasis emerges largely due to the immune system, genetics, and environmental factors. The surge in the number of people affected by psoriasis in recent years can primarily be linked to environmental changes, stress, and unhealthy living conditions. The World Psoriasis Day consortium reveals that psoriasis affects 125 million individuals worldwide, accounting for 2 to 3% of the total population. Consequently, the escalating prevalence of psoriasis is anticipated to stimulate the expansion of the psoriasis market over the projected period.

Which Primary Segments of the Psoriasis Market Are Driving Growth and Industry Transformations?

The psoriasis market covered in this report is segmented –

1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor

2) By Drug Types: Small molecules, Biologics

3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis

4) By Route Of Administration: Oral, Tropical, Injectable

5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce

Subsegments:

1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)

2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)

3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologic Anti-Inflammatory Agents (Apremilast)

4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2414&type=smp

Which Regions Are Key Players in the Growth of the Psoriasis Market?

North America was the largest region in the psoriasis market in 2023. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Psoriasis Market?

The psoriasis market is witnessing a rising trend in the form of combination therapy, an innovative treatment approach that merges two diverse psoriasis treatments concurrently. The impact of merging two drugs with unique mechanisms of action, known as combination therapy, surpasses the outcome derived from monotherapy, which incorporates only a single drug. Research indicates that combination therapy alleviates psoriasis symptoms more efficiently than solitary therapy and has fewer side effects. Eli Lilly and Company devised a perfect example of combination therapy through Taltz (ixekizumab) and methotrexate for the management of active psoriatic arthritis (PsA).

View the full report here:

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

What Parameters Are Used to Define the Psoriasis Market?

Psoriasis refers to a skin condition that typically affects the knees, elbows, trunk, and scalp and results with a rash with itchy, scaly spots. The primary contributing factor may be an immune system issue wherein infection-fighting cells unintentionally kill healthy skin cells.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2414

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.